Please use this identifier to cite or link to this item:
Title: C-kit expression in human osteosarcoma and in vitro assays
Authors: Miiji, Luciana Nakao Odashiro [UNIFESP]
Petrilli, Antonio Sergio [UNIFESP]
Di Cesare, Sebastian
Odashiro, Alexandre Nakao [UNIFESP]
Burnier, Miguel Noel Nascente [UNIFESP]
Toledo, Silvia Regina Caminada de [UNIFESP]
Garcia, Reynaldo Jesus
Alves, Maria Teresa de Seixas [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
McGill Univ
Ctr Hosp Afillie Univ Quebec
Keywords: Osteosarcoma
in vitro assays
Issue Date: 1-Jan-2011
Publisher: E-century Publishing Corp
Citation: International Journal Of Clinical And Experimental Pathology. Madison: E-century Publishing Corp, v. 4, n. 8, p. 775-781, 2011.
Abstract: Biologic agents targeting oncogenes have encourage researchs trying to correlate the role of tyrosine kinase in the pathogenesis of tumours. Osteosarcoma is a high grade aggressive neoplasm with poor survival. Our aim was to investigate c-kit immunoexpression, its prognostic relevance for patients with osteosarcoma, and the effect of imatinib mesylate (STI571) on proliferation and invasion of the human osteosarcoma cell line. A retrospective immunohistochemical study was performed on archival formalin-fixed paraffin-embedded specimens from 52 patients with high-grade primary osteosarcoma of extremities treated at the Pediatric Oncology Institute (IOP, GRAAC) and archived in the Department of Pathology, Federal University of Sao Paulo. Only pre-chemotherapy specimens were analyzed. Strongly stained cytoplasm and membrane cells were taken as positive. Human osteosarcoma cells from line MG-63 were incubated and the inhibitory effect of imatinib mesylate (STI571) on cell proliferation and invasion was studied. In 24 cases (46.15%), c-kit was expressed by the cells and c-kit-positive tumors exhibited lower necrosis post-chemotherapy. No correlation was found between c-kit expression and overall and disease-free survival. Imatinib mesylate decreased the rates of cell growth of osteosarcoma cells in low doses and invasion in high doses C-kit-positive tumors had worse response to chemotherapy and imatinib mesylate can play a role in blocking or decreasing the rate of growth of osteosarcoma cells, but not the invasive capacity of these neoplastic cells. These data suggested that imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors. Further studies are necessary to confirm this indication.
ISSN: 1936-2625
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
File SizeFormat 
WOS000298346300006.pdf579.8 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.